Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04259047 · ClinicalTrials.gov registry record · Phase 2
Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: a Randomized Clinical Trial
A Phase 2 study of Diabetes and Mild Cognitive Impairment, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
- 1
- Study location
NCT04259047 is a Phase 2 study of Diabetes and Mild Cognitive Impairment that has completed, run by Thomas Jefferson University. The registered enrollment target is 145 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04259047, a Phase 2 study of Diabetes and Mild Cognitive Impairment, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
- 1
- Study location
Study Summary
This double-masked, 2-year, single-site, phase II RCT will test the efficacy of DREAM (Diabetes Regulation for Eye Sight and Memory to prevent cognitive decline in African Americans (AAs) with amnestic multiple domain mild cognitive impairment (MCI) and poorly controlled diabetes (i.e., hemoglobin A1c \[HbA1c\] level ≥ 7.5%). Participants will be randomized to DREAM \[11 home-based treatment sessions with a community health worker (CHW), and 4 telehealth visits with a Diabetes Nurse Educator over 2 years\] or Enhanced Usual Care (EUC), which is usual care enhanced with home-based diabetes education. The primary outcome is decline in verbal memory over 2 years. Follow-up data will be collected at 6, 12, 18, and 24 months. In addition, participants will have ophthalmology assessments (at Wills) at baseline, 12 and 24 months to determine whether retinal Vessel Area Density, and/or Retinal Nerve Fiber Layer thickness mediate DREAM's treatment effect.
Conditions Studied
Interventions
- BEHAVIORAL Enhanced Usual Care
- BEHAVIORAL Diabetes Regulation for Eyesight and Memory
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04259047
The ClinicalTrials.gov registry entry for NCT04259047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Enhanced Usual Care is the first listed.
NCT04259047 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04259047 about?
NCT04259047 is a clinical study titled "Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: a Randomized Clinical Trial". This double-masked, 2-year, single-site, phase II RCT will test the efficacy of DREAM (Diabetes Regulation for Eye Sight and Memory to prevent cognitive decline in African Americans (AAs) with amnestic multiple domain mild cognitive impairment (MCI) and poorly controlled diabetes (i.e., hemoglobin A...
What is the current status of trial NCT04259047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2021-10-25. Estimated completion is 2024-08-31.
What conditions does trial NCT04259047 study?
This clinical trial studies the following conditions: Diabetes, Mild Cognitive Impairment.
What interventions are being tested in trial NCT04259047?
The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), Diabetes Regulation for Eyesight and Memory (BEHAVIORAL).
Who is sponsoring clinical trial NCT04259047?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04259047 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
RECRUITING · Phase 2
-
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
ACTIVE NOT RECRUITING · Phase 2
-
Biomarker Guided Therapies in Stage A/B Heart Failure
COMPLETED · Phase 2
-
Effects of Human Leptin Replacement
COMPLETED · Phase 2
-
A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.